紫杉醇联合卡铂同步放疗治疗非小细胞肺癌的临床疗效及安全性研究  

Clinical efficacy and safety of paclitaxel combined with carboplatin concurrent radiotherapy in the treatment of non-small cell lung cancer

作　　者：邵思维 刘亚楠 李洁[1] SHAO Siwei;LIU Ya’nan;LI Jie(Department of Pharmacy,Yancheng No.1 People’s Hospital,Affiliated Hospital of Medical School,Nanjing University/the First People’s Hospital of Yancheng,Yancheng 224000,Jiangsu,China)

机构地区：[1]南京大学医学院附属盐城第一医院/盐城市第一人民医院药学部,江苏盐城224000

出　　处：《癌症进展》2025年第4期437-440,444,共5页Oncology Progress

基　　金：江苏省药学会基金课题(H202318)。

摘　　要：目的探究紫杉醇联合卡铂同步放疗治疗非小细胞肺癌的临床疗效及安全性。方法将非手术治疗的138例非小细胞肺癌患者按照随机抽签的分组法分为对照组和观察组,每组69例,对照组患者采取放疗,观察组患者采用紫杉醇联合卡铂同步放疗。比较两组患者的疗效、肿瘤体积、生活质量[世界卫生组织生活质量测评表-100(WHOQOL-100)]、肿瘤标志物[神经元特异性烯醇化酶(NSE)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]及不良反应。结果观察组患者疗效优于对照组,不良反应总发生率低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者肿瘤体积均缩小,且观察组患者肿瘤体积小于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者WHOQOL-100各维度评分均升高,且观察组患者WHOQOL-100各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者NSE、CYFRA21-1水平均降低,且观察组患者NSE、CYFRA21-1水平均低于对照组,差异均有统计学意义(P﹤0.05)。结论紫杉醇联合卡铂同步放疗对非小细胞肺癌患者具有较好的应用效果,可降低患者肿瘤体积和相关标志物水平,改善生活质量,并提高整体疗效,且具有较少的不良反应,值得推广并运用于临床。Objective To investigate the clinical efficacy and safety of paclitaxel combined with carboplatin concurrent radiotherapy in the treatment of non-small cell lung cancer.Method An aggregate of 138 patients with non-small cell lung cancer were randomly divided into the control group and the observation group,69 cases in each group.The control group was treated with radiotherapy,the observation group was treated with paclitaxel combined with carboplatin concurrent radiotherapy.The efficacy,tumor volume,quality of life[World Health Organization quality of life-100(WHOQOL-100)],tumor markers[neuron-specific enolase(NSE),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)]and adverse reactions were compared between the two groups.Result The curative effect of the observation group was better than that of the control group,and the total incidence of adverse reactions was lower than that of the control group,the differences were statistically significant(P<0.05).After treatment,the tumor volume of the two groups was reduced,and the tumor volume of the observation group was smaller than that of the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of all dimensions of WHOQOL-100 in the two groups increased,and the scores of all dimensions of WHOQOL-100 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of NSE and CYFRA21-1 in the two groups decreased,and the levels of NSE and CYFRA21-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Paclitaxel combined with carboplatin concurrent radiotherapy has a good application effect on patients with non-small cell lung cancer,which can reduce the tumor volume and the level of related markers,improve the quality of life and the overall efficacy,and has less adverse reactions,which is worthy of promotion and application in clinical.

关 键 词：紫杉醇 卡铂 同步放化疗 非小细胞肺癌 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]